ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

ClinicalTrials.gov ID: NCT06008093

Public ClinicalTrials.gov record NCT06008093. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for First-line Treatment in Metastatic Non-small Cell Lung Cancer Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

Study identification

NCT ID
NCT06008093
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AstraZeneca
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Cisplatin Drug
  • Durvalumab Drug
  • Pembrolizumab Drug
  • Pemetrexed Drug
  • Tremelimumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 130 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 3, 2024
Primary completion
Dec 7, 2026
Completion
Dec 22, 2027
Last update posted
Mar 29, 2026

2024 – 2027

United States locations

U.S. sites
47
U.S. states
20
U.S. cities
43
Facility City State ZIP Site status
Research Site Beverly Hills California 90211
Research Site La Jolla California 92093
Research Site Los Alamitos California 90720
Research Site Los Angeles California 90034
Research Site Santa Monica California 90404
Research Site Washington D.C. District of Columbia 20007
Research Site Fort Lauderdale Florida 33308
Research Site Jupiter Florida 33458
Research Site Ocala Florida 34474
Research Site Orlando Florida 32804
Research Site St. Petersburg Florida 33705
Research Site Atlanta Georgia 30318
Research Site Atlanta Georgia 30322
Research Site Honolulu Hawaii 96813
Research Site Carterville Illinois 62918
Research Site Urbana Illinois 61801
Research Site Bethesda Maryland 20817
Research Site Jamaica Plain Massachusetts 02130
Research Site Saint Paul Minnesota 55101
Research Site Kansas City Missouri 64132
Research Site St Louis Missouri 63128
Research Site Billings Montana 59102
Research Site Grand Island Nebraska 68803
Research Site Lincoln Nebraska 68506
Research Site Albany New York 12206
Research Site East Syracuse New York 13057
Research Site New York New York 10032
Research Site Shirley New York 11967
Research Site Stony Brook New York 11790
Research Site Syracuse New York 13210
Research Site The Bronx New York 10461
Research Site Cleveland Ohio 44111
Research Site Cleveland Ohio 44124
Research Site Cleveland Ohio 44195
Research Site Columbus Ohio 43210
Research Site Dayton Ohio 45459
Research Site Norman Oklahoma 73072
Research Site Pittsburgh Pennsylvania 15212
Research Site Sioux Falls South Dakota 57105
Research Site Memphis Tennessee 38120
Research Site Dallas Texas 75246
Research Site Denton Texas 76210
Research Site Houston Texas 77030
Research Site Houston Texas 77090
Research Site Kingwood Texas 77339
Research Site Fairfax Virginia 22031
Research Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06008093, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2026 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06008093 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →